JB Chemicals & Pharmaceuticals Limited

rs,

ironment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company

INR3,918

not be copied or disseminated, in whole or in part, and in any manner. 2 JB Pharma At A Glance INR3,918 Cr 6 Top 5 FY25 Revenue Brands in IPM Top 300 CDMO of Lozenges Globally Scale Domestic Growt

58%

ter excluding non-cash ESOP Charge 3. ROCE = EBIT/(Net Worth + Net Debt - Mutual Fund Investments) 58% Domestic Revenue% (FY25) 1.6x Outperformance vs IPM (MAT Jun’25) 27.7% Operating EBITDA Mar

1.6x

ge 3. ROCE = EBIT/(Net Worth + Net Debt - Mutual Fund Investments) 58% Domestic Revenue% (FY25) 1.6x Outperformance vs IPM (MAT Jun’25) 27.7% Operating EBITDA Margin% (FY25) #16 Prescription Ra

27.7%

utual Fund Investments) 58% Domestic Revenue% (FY25) 1.6x Outperformance vs IPM (MAT Jun’25) 27.7% Operating EBITDA Margin% (FY25) #16 Prescription Rank (FY25) 17% Revenue CAGR (FY22-25) 17%

17%

ance vs IPM (MAT Jun’25) 27.7% Operating EBITDA Margin% (FY25) #16 Prescription Rank (FY25) 17% Revenue CAGR (FY22-25) 17% PAT Margin% (FY25) 47% FY25 Chronic%(1) 20% Operating EBITDA CAGR

47%

rgin% (FY25) #16 Prescription Rank (FY25) 17% Revenue CAGR (FY22-25) 17% PAT Margin% (FY25) 47% FY25 Chronic%(1) 20% Operating EBITDA CAGR (FY22-25)(2) 32% ROCE (FY25(3) 3 3 Q1 FY26 Busi

20%

cription Rank (FY25) 17% Revenue CAGR (FY22-25) 17% PAT Margin% (FY25) 47% FY25 Chronic%(1) 20% Operating EBITDA CAGR (FY22-25)(2) 32% ROCE (FY25(3) 3 3 Q1 FY26 Business Performance 4 CE

32%

(FY22-25) 17% PAT Margin% (FY25) 47% FY25 Chronic%(1) 20% Operating EBITDA CAGR (FY22-25)(2) 32% ROCE (FY25(3) 3 3 Q1 FY26 Business Performance 4 CEO’s Message – Q1 FY26 “ “JB continues t

14%

amongst top 25 organizations as per IQVIA MAT Jun’25 data. The domestic business recorded approx. 14% value growth. This was driven by acute and chronic segments, including our ophthalmology portfoli

30%

O business momentum is likely to sustain in coming quarters. Our Operating EBITDA* margins crossed 30% for the first time, which highlights the results of our strategy of focusing on profitable growth

12%

iews on Q1 FY26 business performance Results Overview: Q1 FY26 vs Q1 FY25 Revenues (INR crores) 12% 3,484 3918 9% 1,004 1,094 Q1 FY25 Q1 FY26 FY24 FY25 18 115 76 446 Q1 FY26 283 678